Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: A Joint Evidence-Based Guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)

Barbosa, Alexandre Naime; Chebabo, Alberto; Starling, Carlos Ernesto Ferreira; Pérez, Clevy; Cunha, Clóvis Arns da; Luna, David de; Nunes, Estêvão Portela; Zambrano, Gabriela; Ferreira, Juliana Carvalho; Croda, Júlio; Falavigna, Maicon; Silva, Monica Maria Gomes da; Thormann, Mónica; Cimerman, Sérgio; Parahiba, Suena Medeiros; Tanni, Suzana Erico; Bernardo, Wanderley Marques; Rodríguez‐Morales, Alfonso J.

doi:10.21203/rs.3.rs-2603347/v1

Cited by 2 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment strategies were also implemented. Recently, a pan-American guideline indicated the use of different antivirals according to patient characteristics and clinical presentation, with a strong recommendation for the use of nirmatrelvir/ritonavir in outpatients with mild COVID-19 [7]. Clear documentation of antiviral access and availability in the region is not available.…”

Section: Introductionmentioning

confidence: 99%

Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era

Silva Julian,

Spinardi,

Diaz-Puentes

et al. 2024

Viruses

View full text Add to dashboard Cite

We conducted a multicountry retrospective study using data from COVID-19 national surveillance databases to analyze clinical profiles, hospitalization rates, intensive care unit (ICU) admissions, utilization of ventilatory support, and mortality rates in five Latin American countries in the context of COVID-19 vaccination implementation. We analyzed the sociodemographic characteristics, comorbidities, clinical outcomes, and vaccination status of laboratory-confirmed COVID-19 cases from January 2021 to December 2022. We calculated the yearly and quarterly hospitalization rates per 1000 confirmed COVID-19 cases and ICU admissions, use of mechanical ventilators, and mortality rates per 1000 hospitalized cases, with their corresponding 95% confidence interval (CI) of 38,852,831 confirmed COVID-19 cases. Rates of hospitalization, ICU admission, ventilatory support, and death were higher among males than among females (38.2 vs. 32.4, 148.4 vs. 117.7, 282.9 vs. 236.2, and 346.9 vs. 320.1 per 1000, respectively); higher in 2021 than in 2022 (50.7 vs. 19.9, 207.8 vs. 58.2, 441.5 vs. 114.9, and 352.5 vs. 285.2 per 1000, respectively); and in the >50 age group (range: 5.7–18.6, 20.1–71.5, 12.2–67.9, and 353.1–577.4, per 1000) than the <50 age group (range: 2.2–9.3, 5.4–33.2, 41.4–135.8, and 22–243.5 per 1000). Hypertension and diabetes mellitus were the most common comorbidities in Mexico and Colombia. Prevention and treatment strategies for these case profiles could bring benefits from a public health perspective.

show abstract

Section: Introductionmentioning

confidence: 99%

Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era

Silva Julian,

Spinardi,

Diaz-Puentes

et al. 2024

Viruses

View full text Add to dashboard Cite

show abstract

“…With these premises, we believe that antiviral drugs still have a clear indication in the early treatment of patients with COVID-19 and risk factors for a poor clinical course, particularly when other treatments such as monoclonal antibodies do not seem effective at present. Several institutions have issued recent recommendations on various aspects of treatment and in particular on antiviral treatment [62,63].…”

Section: What Should Be the Antiviral Treatment Of Patients With Covi...mentioning

confidence: 99%

COVID -19: On the threshold of the fifth year. The situation in Spain

Rodríguez-Artalejo,

Ruiz-Galiana,

Cantón

et al. 2023

Rev Esp Quimioter

View full text Add to dashboard Cite

Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising from two Omicron BA.2 sublineages with mutations in the genes encoding the spicule proteins that could increase binding to the ACE2 receptor and be more prone to immune escape. Faced with these, 3 pharmaceutical companies have developed vaccines adapted to the XBB.1.5 sublineage that are already available for administration in our setting with risks that should not be different from those of previous mRNA vaccines and with clearly favorable benefit/risk ratios. They should be applied to patients with potential for poor COVID-19 evolution and to collectives that have a particular relationship of proximity with them. Their application should be understood not only from a perspective of individual convenience but also from that of collective responsibility. The most convenient seems to be a simultaneous immunization of COVID-19 and influenza in our environment. In the therapeutic aspect, there is little to expect right now from antisera, but the already known antiviral drugs are still available and indicated, although their efficacy will have to be reevaluated due to their impact on populations that are mostly immunized and with a better prognosis than in the past. In our opinion, it is necessary to continue to make a reasonable and timely use of masks and other non-pharmacological means of protection.

show abstract

Pan-American Guidelines for the Treatment of SARS-CoV-2/COVID-19: A Joint Evidence-Based Guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)

Cited by 2 publications

References 56 publications

Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era

Severe COVID-19 Outcomes in Five Latin American Countries in the Postvaccination Era

COVID -19: On the threshold of the fifth year. The situation in Spain

Contact Info

Product

Resources

About